How can we best monitor 5-FU administration to maximize benefit to risk ratio?

References

• van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40:939–950.
   PubMed Web of Science ®Google Scholar
• Tsalic M, Bar-Sela G, Beny A, et al. Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. Am J Clin Oncol. 2003;26:103–106.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, Henricks LM, Jacobs BAW, et al. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116:1415–1424.
   PubMed Web of Science ®Google Scholar
• Marques RP, Duarte GS, Sterrantino C, et al. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;118:54–62.
   PubMed Web of Science ®Google Scholar
• Loriot MA, Ciccolini J, Thomas F, et al. [Dihydropyrimidine dehydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks]. Bull Cancer. 2018;105:397–407.
   PubMed Web of Science ®Google Scholar
• Meulendijks D, Cats A, Beijnen JH, et al. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? Cancer Treat Rev. 2016;50:23–34.
   PubMed Web of Science ®Google Scholar
• Saam J, Critchfield GC, Hamilton SA, et al. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. Clin Colorectal Cancer. 2011;10:203–206.
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Link K, Miller MC, et al. A prospective, multi-center study of individualized, pharmacokinetically (PK)-guided dosing of 5-fluorouracil (5-FU) in metastatic colorectal cancer (mCRC) patients treated with weekly or biweekly 5-FU/oxaliplatin containing regimens. J Clin Oncol. 2015;33.
   Web of Science ®Google Scholar
• Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10:1171–1175.
   PubMed Web of Science ®Google Scholar
• Braiteh FS, Salamone SJ, Li YY, et al. Pharmacokinetic (PK)-guided optimization of 5-fluorouracil (5FU) exposure in colorectal cancer (CRC) patients: uSbased clinical practices experience. J Clin Oncol. 2014;32.
   Web of Science ®Google Scholar
• Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005;5:447–458.
   PubMed Web of Science ®Google Scholar
• Saif MW, Choma A, Salamone SJ, et al. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009;101:1543–1552.
   PubMed Web of Science ®Google Scholar
• Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol. 1999;17:1105.
   PubMed Web of Science ®Google Scholar
• Andre T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;25:3732–3738.
   PubMed Web of Science ®Google Scholar
• Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2099–2105.
   PubMed Web of Science ®Google Scholar
• Gieschke R, Burger HU, Reigner B, et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br J Clin Pharmacol. 2003;55:252–263.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang L, Yan Y, et al. Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis? Drug Metab Dispos. 2015;43:411–417.
   PubMed Web of Science ®Google Scholar
• Hagmann W, Faissner R, Schnolzer M, et al. Membrane drug transporters and chemoresistance in human pancreatic carcinoma. Cancers (Basel). 2010;3:106–125.
   PubMedGoogle Scholar
• Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997;57:3537–3547.
   PubMed Web of Science ®Google Scholar
• Yuan J, Lv H, Peng B, et al. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009;63:1103–1110.
   PubMed Web of Science ®Google Scholar
• Yuan JH, Cheng JQ, Jiang LY, et al. Breast cancer resistance protein expression and 5-fluorouracil resistance. Biomed Environ Sci. 2008;21:290–295.
   PubMed Web of Science ®Google Scholar
• Schaaf LJ, Dobbs BR, Edwards IR, et al. Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. Eur J Clin Pharmacol. 1987;32:411–418.
   PubMed Web of Science ®Google Scholar
• Oguri T, Bessho Y, Achiwa H, et al. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther. 2007;6:122–127.
   PubMed Web of Science ®Google Scholar
• Nambaru PK, Hubner T, Kock K, et al. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. Drug Metab Dispos. 2011;39:132–139.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Thorn CF, Klein TE, et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94:640–645.
   PubMed Web of Science ®Google Scholar
• Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995;75:11–17.
   PubMed Web of Science ®Google Scholar
• Ansfield FJ, Schroeder JM, Curreri AR. Five years clinical experience with 5-fluorouracil. JAMA. 1962;181:295–299.
   PubMed Web of Science ®Google Scholar
• Fleming RA, Milano GA, Etienne MC, et al. No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion. Br J Cancer. 1992;66:668–672.
   PubMed Web of Science ®Google Scholar
• Morawska K, Goirand F, Marceau L, et al. 5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer. Oncotarget. 2018;9:11559–11571.
   PubMedGoogle Scholar
• Terret C, Erdociain E, Guimbaud R, et al. Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin Pharmacol Ther. 2000;68:270–279.
   PubMed Web of Science ®Google Scholar
• Grem JL, Quinn M, Ismail AS, et al. Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion. Cancer Chemother Pharmacol. 2001;47:117–125.
   PubMed Web of Science ®Google Scholar
• Ismail AS, Quinn MG, Wright MA, et al. A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. Oncol Rep. 2005;13:1145–1152.
   PubMed Web of Science ®Google Scholar
• Gusella M, Crepaldi G, Barile C, et al. Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. Ann Oncol. 2006;17:1656–1660.
   PubMed Web of Science ®Google Scholar
• Patel JN, O’Neil BH, Deal AM, et al. A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. Oncologist. 2014;19:959–965.
   PubMed Web of Science ®Google Scholar
• Capitain O, Asevoaia A, Boisdron-Celle M, et al. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer. 2012;11:263–267.
   PubMed Web of Science ®Google Scholar
• Ma Y, Lin Y, Zou B, et al. Pharmacokinetic and pharmacodynamic analyses of 5-fluorouracil in east-asian patients with nasopharyngeal carcinoma. Clin Pharmacokinet. 2016;55:1205–1216.
   PubMed Web of Science ®Google Scholar
• Ychou M, Duffour J, Kramar A, et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol. 2003;52:282–290.
   PubMed Web of Science ®Google Scholar
• Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer. 1996;77:441–451.
   PubMed Web of Science ®Google Scholar
• Blaschke M, Cameron S, Goeschen C, et al. 5-FU schedules, serum 5-FU levels and their relationship to therapy response and toxicity in patients with gastrointestinal cancer. Int J Clin Pharmacol Ther. 2013;51:56–58.
   PubMed Web of Science ®Google Scholar
• Special report: laboratory testing to allow area under the curve (AUC)-targeted 5-fluorouracil dosing for patients administered chemotherapy for cancer. Technol Eval Cent Assess Program Exec Summ. 2010;24:1–3.
   Google Scholar
• Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res. 1998;4:2039–2045.
   PubMed Web of Science ®Google Scholar
• Woloch C, Di Paolo A, Marouani H, et al. Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. Curr Top Med Chem. 2012;12:1713–1719.
   PubMed Web of Science ®Google Scholar
• Hillcoat BL, McCulloch PB, Figueredo AT, et al. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer. 1978;38:719–724.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808–815.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947.
   PubMed Web of Science ®Google Scholar
• Wihlm J, Leveque D, Velten M, et al. [Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion]. Bull Cancer. 1993;80:439–445.
   PubMedGoogle Scholar
• Kline CL, Sheikh HS, Scicchitano A, et al. Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biol Ther. 2011;12:557–568.
   PubMed Web of Science ®Google Scholar
• Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer. 1989;59:287–290.
   PubMed Web of Science ®Google Scholar
• Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol. 1998;16:1470–1478.
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Mueller L, Miller MC, et al. Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal cancer treated in routine clinical practice. Clin Colorectal Cancer. 2016;15:381–388.
   PubMed Web of Science ®Google Scholar
• Petit E, Milano G, Levi F, et al. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res. 1988;48:1676–1679.
   PubMed Web of Science ®Google Scholar
• Levi FA, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst. 1994;86:1608–1617.
   PubMed Web of Science ®Google Scholar
• Jacobs BA, Deenen MJ, Pluim D, et al. Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers. Br J Clin Pharmacol. 2016;82:706–716.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Bjarnason G, Garufi C, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol. 2006;24:3562–3569.
   PubMed Web of Science ®Google Scholar
• Milano G, Etienne MC. [Evolution from pharmacokinetics to pharmacogenetics. The example of 5-fluorouracil]. Rev Med Interne. 1994;15:287–291.
   PubMed Web of Science ®Google Scholar
• Thyss A, Milano G, Renee N, et al. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol. 1986;16:64–66.
   PubMed Web of Science ®Google Scholar
• Kaldate RR, Haregewoin A, Grier CE, et al. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist. 2012;17:296–302.
   PubMed Web of Science ®Google Scholar
• Kline CL, Schiccitano A, Zhu J, et al. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. Clin Colorectal Cancer. 2014;13:119–126.
   PubMed Web of Science ®Google Scholar
• Salman D, Barton S, Nabhani-Gebara S. Effect of environmental conditions on performance of elastomeric pumps. Am J Health Syst Pharm. 2013;70:1100.
   PubMedGoogle Scholar
• Etienne MC, Lagrange JL, Francois E, et al. Portable pumps in cancer chemotherapy: how to deal with marked fluctuations in 5-fluorouracil blood concentrations. Eur J Cancer. 1995;31A:2414–2415.
   PubMed Web of Science ®Google Scholar
• Boisdron-Celle M, Le Guellec C. Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de T. [Therapeutic drug monitoring of 5-fluorouracil after its administration in high-dose protocols]. Therapie. 2010;65:171–176.
   Google Scholar
• Murphy RF, Balis FM, Poplack DG. Stability of 5-fluorouracil in whole blood and plasma. Clin Chem. 1987;33:2299–2300.
   PubMed Web of Science ®Google Scholar
• Gamelin E, Bouil AL, Boisdron-Celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin Cancer Res. 1997;3:891–899.
   PubMed Web of Science ®Google Scholar
• Deng P, Ji C, Dai X, et al. Simultaneous determination of capecitabine and its three nucleoside metabolites in human plasma by high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015;989:71–79.
   PubMed Web of Science ®Google Scholar
• Montange D, Berard M, Demarchi M, et al. An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma. J Mass Spectrom. 2010;45:670–677.
   PubMed Web of Science ®Google Scholar
• Chavani O, Jensen BP, Strother RM, et al. Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, alpha-fluoro-beta-ureidopropionic acid and alpha-fluoro-beta-alanine in human plasma. J Pharm Biomed Anal. 2017;142:125–135.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Boisdron-Celle M, Clarke W, et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit. 2009;31:688–694.
   PubMed Web of Science ®Google Scholar
• Becker R, Hollenbeak CS, Choma A, et al. Cost-effectiveness of pharmacokinetic dosing of 5-fluorouracil in metastatic colorectal cancer in the United Kingdom. Value Health. 2013;16:A139–A139.
   Web of Science ®Google Scholar
• Goldstein DA, Chen Q, Ayer T, et al. Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer. 2014;13:219–225.
   PubMed Web of Science ®Google Scholar
• Beumer JH, Chu E, Allegra C, et al. Therapeutic drug monitoring in oncology: IATDMCT recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther. 2018.
   PubMed Web of Science ®Google Scholar